Developing a Phenotypic In Vitro Model for Progression of Liver Steatosis


Hepatic steatosis, a reversible state of metabolic dysregulation, is the first step in the progression of nonalcoholic fatty liver disease (NAFLD). It is characterized by excessive intracellular lipid accumulation and can progress to nonalcoholic steatohepatitis (NASH) and hepatocellular injury. Currently, there are no FDA-approved medicines to treat NAFLD or NASH, and the complex molecular and genetic mechanisms are not completely understood. To address this, Siobhan Malany, from the Conrad Prebys Center for Chemical Genomics in Florida, US, and colleagues developed a model of hepatic steatosis in functional human induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep).